Explore News By Topic

07/20/2020

Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program

When prostate cancer progresses to a more-dangerous metastatic state, it does so by resurrecting dormant molecular mechanisms that had guided the fetal development of the prostate gland but had been subsequently switched off, say scientists from Dana-Farber Cancer Institute. The study, an international collaboration with The Netherlands Cancer Institute, was published in Nature... Read More

07/07/2020

The Prostate Cancer Foundation Collaboration with Pan-Cancer Consortium Clarifies and Promotes Consistent Use of Common Terms for Biomarker and Germline Genetic Testing

LOS ANGELES, Calif., July 7, 2020 — The Prostate Cancer Foundation (PCF) has collaborated with a consortium of 41 leading patient advocacy organizations, professional societies and industry partners to publish a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer... Read More

06/09/2020

New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer

PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven prostate cancer genetic implementation framework for the precision medicine era. The consensus framework is a... Read More

05/30/2020

ASCO 2020: Blood Test Predicts Response to Prostate Cancer Treatment

A new blood test can predict how well men with advanced prostate cancer will respond to treatment and could replace some of the existing methods used to characterise and track the disease. The non-invasive test is less painful and cheaper than tissue biopsies and can help pick out men who... Read More

05/15/2020

Rubraca® (Rucaparib) Approved In The U.S. As Monotherapy Treatment For Patients With BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (MCRPC) Who Have Been Treated With Androgen Receptor-Directed Therapy And A Taxane-Based Chemotherapy

Rubraca is the first PARP inhibitor approved in a prostate cancer setting Accelerated approval based on objective response rate (ORR) and duration of response (DOR) data from the TRITON2 clinical trial i 44% ORR (95% CI 31, 57) and median DOR not evaluable (95% CI 6.4, NE, range in months... Read More

05/15/2020

VA Launches Clinical Trial for Veterans with COVID-19 Based on Prostate Cancer Drug

WASHINGTON — Today, the U.S. Department of Veterans Affairs (VA) began a new clinical trial to test a Food and Drug Administration-approved prostate cancer drug as a potential treatment for male Veterans with COVID-19. In a double-blind randomized controlled trial, VA scientists will compare the drug degarelix (trade name Firmagon) to a placebo... Read More

04/28/2020

Major Trial Shows Breast Cancer Drug Can Hit Prostate Cancer Achilles Heel

Olaparib, licensed for breast and ovarian cancer, is effective for some men with prostate cancer too Drug better than targeted hormone therapy in cancers with weaknesses in repairing their DNA Major clinical trial heralds approval as first gene-targeted drug in prostate cancer A drug already licensed for the treatment of... Read More

04/14/2020

Prostate Cancer Foundation and MIT Researcher Develops Revolutionary Re-Useable Personal Protective Mask to Battle COVID-19

WHAT: To combat the short supply and high demand for the personal protective equipment (PPE) needed to safeguard medical professionals and first responders in the battle against the COVID-19 global crisis, Prostate Cancer Foundation (PCF) Young Investigator and Massachusetts Institute of Technology (MIT) researcher and physician, James Byrne, M.D., Ph.D.,... Read More

03/25/2020

The Second Annual PCF Black History Month Assist Challenge sets new Fundraising Record by raising more than $500,000 for Prostate Cancer Research

LOS ANGELES, Calif., March 25, 2020 – In its sophomore year, the Second Annual Prostate Cancer Foundation Black History Month Assist Challenge more than tripled its fundraising efforts, compared to 2019,  by raising more than $500,000 to combat prostate cancer, a disease that affects more than three million men in... Read More

03/22/2020

Molecular Imaging Could Transform Management of People with Aggressive Cancer

VICTORIA, Australia, March 22, 2020: A medical imaging technique known as PSMA PET/CT that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for their patients, by determining the extent of disease spread at the time of diagnosis, a randomised... Read More